利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

111 条记录 (耗时 0.022 秒)

    METHOD FOR MANUFACTURING DIARYLMETHANE COMPOUND
    2.
    发明公开
    METHOD FOR MANUFACTURING DIARYLMETHANE COMPOUND 审中-公开

    公开(公告)号：EP3805211A1

    公开(公告)日：2021-04-14

    申请号：EP19811933.1

    申请日：2019-05-30

    申请人： Tokuyama Corporation

    发明人： SEKI Masahiko

    IPC分类号： C07D333/12

    摘要： An object is to provide a method for producing a compound which is useful as a synthetic intermediate for an active pharmaceutical ingredient of an antidiabetic drug or the like in an industrially inexpensive and efficient manner, and the present invention can achieve the object by reducing a compound (2) represented by the following formula (2):

    wherein R 1 , Ar, n and X are as mentioned herein in the presence of a titanium compound by using a reducing agent to produce a compound (1) represented by the following formula (1):

    wherein R 1 , Ar and n are the same as defined above.

    PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS
    9.
    发明授权
    PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS 有权
    程序用于获得度洛西汀前体对映体

    公开(公告)号：EP1989193B1

    公开(公告)日：2011-06-22

    申请号：EP07711690.3

    申请日：2007-02-27

    申请人： Laboratorios del. Dr. Esteve, S.A.

    发明人： BUSCHMANN, Helmut Heinrich ,  TORRENS JOVER, Antoni ,  LORMANN, Matthias ,  DAHMEN, Stefan

    IPC分类号： C07D333/12 ,  C07D333/14 ,  C07D333/24

    CPC分类号： C07D333/24 ,  C07D333/12 ,  C07D333/14 ,  Y02P20/55

    摘要： The present invention is directed to a process for the preparation of an enantiomerically enriched compound of formula (II) wherein, R1, R2 and R3 are each independently selected from hydrogen, halogen, substituted or unsubstituted lower alkyl or substituted or unsubstituted aryl; X is -C(=O)-Z or -Y, wherein -Y is selected from -CH2-OR4, -CH2-halogen or -CH2-NR6R7; wherein Z is selected from -NR6R7 or -OR5, wherein R5 is selected from hydrogen, substituted or unsubstituted lower alkyl or ester activating group; R4 is selected from hydrogen, hydroxyl protecting group or hydroxyl activating group; R6 and R7 are each independently selected from hydrogen, amino protecting group, amido protecting group or substituted or unsubstituted lower alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof; which comprises an enantioselective addition with a thienyl zinc reagent, in the presence of a chiral ligand.